psalexa
SearchBar Icon

Rectal Cancer Therapeutics Pipeline is Witnessing Significant Growth due to Growing Need for Targeted Therapies

Published Date:   March 2018

Rectal cancer therapeutics currently exhibits a proliferating pipeline with 15 drug candidates, P&S Market Research.

Browse report overview with detailed TOC on "Rectal Cancer Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" at:https://www.psmarketresearch.com/market-analysis/rectal-cancer-therapeutics-pipeline-analysis

Rectal Cancer Therapeutics Pipeline in 2018

Rectal cancer is a disease in which malignant (cancer) cells are formed in the tissues of the rectum. The rectum is the lower part of the colon that connects the large bowel to the anus. It starts at the end of the final segment of the colon and ends when it reaches the short, narrow passage leading to the anus. Adenocarcinomas or cancer in the epithelium, comprise the vast majority of colon and rectal cancers; some of the rare rectal cancers include lymphoma, carcinoid and sarcoma. It has been observed that, there are no early symptoms of rectal cancer, but some of the generalized symptoms include, pain in rectum, change in appetite, fatigue or tiredness, unintended weight loss and stomach cramps.

Insights on Pipeline Segments

According to the research findings, most of the drug candidates for the treatment of rectal cancer are being developed to be administered by the intravenous and the oral route. The main advantage associated with the intravenous route is that the drug can easily be entered the bloodstream, or lymph vessels. Also, medication can be easy to take through the oral route, additionally the route has very less patient non-compliance.

Rectal Cancer Therapeutics Pipeline is Witnessing Significant Growth due to Growing Need for Targeted Therapies

It has been observed that most of the therapeutics that are being developed for acting on the specific target, and interventional studies including targeted therapeutics for the treatment of rectal cancer, have showed positive efficacy in the clinical as well as Pre-Clinical stage of development. An example of such therapy includes, Ziv-aflibercept, a fusion protein, under the Phase II stage of development by Sanofi S.A. for the treatment of rectal cancer. Ziv-aflibercept has been approved by USFDA for use in combination with 5-fluorouracil, leucovorin, and irinotecan in patients with metastatic colorectal cancer and rectal cancer.

Growing Geriatric Population to Immensely Support Rectal Cancer Therapeutics Pipeline Growth

It has been observed that, rise in geriatric population and increasing incidence of rectal cancer has been driving the growth of the rectal cancer pipeline. Colorectal cancer includes both colon and rectal cancers. According to the National Cancer Institute, in 2017, the incident cases of colorectal cancer were found as 40.1 per 100,000 people per year. The increasing geriatric population is mostly frail and unable to tolerate the treatments such as radiation therapy and chemotherapy for the treatment of cancer. This is one of the most prominent factor due to which companies are focusing towards development of therapeutics for the treatment of rectal cancer.

Some of the key players involved in the development of rectal cancer therapeutics include Taiwan Liposome Company, Sanofi and Advaxis Inc.

Rectal Cancer Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company